Cancer

Adaptive Research Welcomes Western Radiation Oncology to Expand Community Access to Pioneering Cancer Treatment Trials

SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Adaptive Research and Western Radiation Oncology (WRO) have announced that WRO has…

1 month ago

New Technology from Riverain Adds Coronary Artery Calcification Scoring to Ungated Chest CT Scans

Incidental CAC Scores Now Possible with ClearRead™ CT MIAMISBURG, Ohio, Dec. 3, 2024 /PRNewswire/ -- Coronary artery calcification (CAC) affects…

1 month ago

Hollywood Futurist Ted Schilowitz Joins Novobeing as Strategic Investor and Executive Team Member

BOSTON, Dec. 3, 2024 /PRNewswire/ -- Novobeing,a leader in medical virtual reality for enhanced patient care, is proud to welcome…

1 month ago

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

The Acquisition of NexGenAI Affiliates Network Expands Company's Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth WEXFORD, Pa. ,…

1 month ago

Biofrontera Inc. to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing…

1 month ago

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

Building on preclinical success demonstrating age reversal, longevity, and increased healthspan, Telomir-1 appears to address insulin resistance at its root,…

1 month ago

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Milestone Reinforces the Potential for Cytisinicline as a First-in-Class Treatment for Vaping CessationSEATTLE and VANCOUVER, British Columbia, Dec. 03, 2024…

1 month ago

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA) today announced it will investigate the ability of its…

1 month ago